The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.
September 2nd 2021
The universal cancer vaccine UV1 and granulocyte-macrophage colony-stimulating factor in combination with pembrolizumab elicited encouraging initial signs of clinical response with favorable safety and tolerability when used in the first-line treatment of patients with metastatic melanoma, meeting the primary end point of an ongoing phase 1 trial.
August 5th 2021
Dr. Weber discusses exciting research presented during the 2021 ASCO Annual Meeting in melanoma with combination and single-agent checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and more.
April 30th 2021
Arsen Osipov, MD, discusses the role of combination immunotherapy across multiple tumor types.
March 19th 2021
Geoffrey T. Gibney, MD, discusses the potential utility of fixed-duration immunotherapy in melanoma.
February 9th 2021
February 9, 2021 - The FDA has approved cemiplimab-rwlc as the first immunotherapy for use in patients with advanced basal cell carcinoma that has previously been treated with a hedgehog pathway inhibitor (HHI) or for whom a HHI is not appropriate.
January 25th 2021
January 25, 2021 - The FDA has granted toripalimab a fast track designation for use in the frontline treatment of patients with mucosal melanoma.
January 13th 2021
Ryan Sullivan, MD, discusses treatment sequencing with targeted therapy and immunotherapy in melanoma.
January 11th 2021
Mario Sznol, MD, Yale Cancer Center, discusses the multidisciplinary management of toxicities associated with immunotherapy in patients with melanoma.
January 11th 2021
January 11, 2021 — The FDA has granted an orphan drug designation to the novel intratumoral immunotherapy agent PVSRIPO for the treatment of patients with advanced melanoma, specifically those with stage IIIB-IV disease.
January 7th 2021
Mario Sznol, MD, discusses toxicities associated with immunotherapy in patients with melanoma.
December 14th 2020
Mario Sznol, MD, discusses the critical importance of being aware of the immune-related toxicities that could arise when treating patients with cancer, along with the best ways to manage them.
December 7th 2020
In our exclusive interview, Caroline Robert, MD, PhD, discusses her groundbreaking work on clinical trials evaluating anti–CTLA-4 and anti–PD-1 antibodies in advanced melanoma, her experiences as a researcher in France and the United States, her love of traveling, and next steps for the field.
December 3rd 2020
Suthee Rapisuwon, MD, discusses the frontline treatment of acral and mucosal melanoma.
November 5th 2020
Douglas B. Johnson, MD, MSCI, discusses his research examining the impact of body composition on outcomes from anti–PD-1 with or without anti–CTLA-4 therapies in melanoma and other biomarkers under exploration.
October 8th 2020
Suthee Rapisuwon, MD, reviews management strategies under exploration for mucosal, acral, and uveal melanoma.
October 5th 2020
The immunotherapy combination of adjuvant nivolumab and ipilimumab failed to lead to a statistically significant improvement in recurrence-free survival in the intent-to-treat population of patients with resected stage IIIB/C/D or stage IV melanoma.
October 1st 2020
Michael B. Atkins, MD, discusses the clinical impact of key adjuvant and neoadjuvant data in the melanoma space, as well as the risks and benefits of both approaches.
September 19th 2020
Early findings from a phase II efficacy and safety study may be the first step in developing a definitive rationale for sequencing targeted therapies and immunotherapies in patients with metastatic melanoma.
September 17th 2020
In our exclusive interview, Omid Hamid, MD, contextualizes the FDA approval of atezolizumab in combination with cobimetinib and vemurafenib in BRAF V600 mutation–positive advanced melanoma and discusses important takeaways from the IMspire150 trial.